This article was created with Dr. Charles V. Pollack, a consultant clinical scientist and professional educator with Novartis, owner of abelacimab.
The prevalence of atrial fibrillation (AFib) in the United States is on a steep rise, projected to grow from today’s 6 million patients to 12 million by 2030. This irregular heart rhythm is far from benign—it increases a person’s risk of stroke fivefold.
For most, the standard protection against stroke in atrial fibrillation is oral anticoagulation (OAC). But in real-world clinics, a subset of patients face a dangerous dilemma: they are at significant risk of stroke but cannot safely take blood thinners. Clinicians must weigh the stroke risk against the danger of serious bleeding, a balancing act made more difficult when both risks are high.
Certain conditions clearly tip the scale against OAC use. A history of intracranial hemorrhage—whether an intracerebral bleed or a subdural hematoma—often closes the door on long-term anticoagulation. Spontaneous major bleeds, such as retroperitoneal hemorrhage or gastrointestinal bleeding requiring transfusion, may lead to the same decision. Severe intolerance to anticoagulants, recurrent falls in the setting of frailty, advanced kidney disease, specific high-bleeding-risk cancers, thrombocytopenia, or occupational hazards also push patients out of the OAC pathway.
When blood thinners are off the table, how can doctors still protect these patients from stroke? Experts point to a three-pronged approach.
1. Aggressive Risk Factor Modification
Even without OAC, lowering overall cardiovascular risk is crucial. That means strict control of high blood pressure, optimal diabetes management, treatment of high cholesterol, and comprehensive lifestyle measures—quitting smoking, moderating alcohol, managing weight, and exercising regularly. These steps won’t replace anticoagulation but can help reduce overall stroke risk.
2. Closing Off the Left Atrial Appendage
The left atrial appendage (LAA) is the heart’s most common source of clot formation in atrial fibrillation. The Watchman device, inserted via a minimally invasive procedure, seals this pouch and prevents clot escape. Trials like PROTECT-AF and PREVAIL demonstrated its potential, and the ongoing CHAMPION-AF trial (completion expected in 2026) may solidify its place in care. In a registry of 38,000 implants, the device had a 98% success rate, a 2% complication rate, and—in the PINNACLE study—a post-implant stroke rate of just 0.5% with no deaths. Still, experts caution that in the oldest, frailest patients, strokes often come from other causes, making the LAA less central.
3. New-Generation Anticoagulants That Spare Bleeding Risk
A promising frontier is the development of Factor XI inhibitors, such as abelacimab—a once-monthly subcutaneous injection. Factor XI is involved in clot formation but not essential for normal bleeding control. People born without it (hemophilia C) rarely have clots and don’t experience spontaneous bleeding. In trials, abelacimab fully suppressed Factor XI, prevented venous thromboembolism better than enoxaparin, and was safe in over 1,400 treated patients, even through more than 350 surgical procedures, including colonoscopy with polypectomy, spinal fusion, hip replacement, and prostate surgery. The ongoing LILAC-TIMI 76 trial is now enrolling patients unsuitable for OAC due to major bleeding risk, advanced kidney disease, frailty, or multiple falls—offering hope for a group with few options today.
As the atrial fibrillation epidemic grows, so will the number of patients who need stroke protection without the bleeding risk of traditional anticoagulants. From lifestyle optimization to device therapy and novel clot-prevention drugs, the future of care may lie in strategies that protect the brain without endangering the rest of the body.
Leave a Reply